Skip to main content
SpringerLink
Log in

Collagenase Clostridium Histolyticum for the Treatment of Peyronie’s Disease: A ‘Real World’ Clinical Perspective

  • Current Opinion
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The introduction of collagenase Clostridium histolyticum (CCH) as a treatment option for Peyronie’s disease (PD), defined as the abnormal formation of collagen on the tunica albuginea of the penis, has provided patients with a promising new conservative therapy. Studies have shown that CCH improves curvature by an average of 17°, and although patient and sexual partner satisfaction is high, the improvement has arguable clinical implications. Similarly, the efficacy and cost of CCH contrasts strongly with more invasive surgical management, and is further limited by rare, but serious, complications and several contraindications. The future of CCH involves well-designed trials analyzing the effects of CCH on patients who are currently not indicated for therapy, and the optimal amount of treatment for the most efficient treatment possible. CCH provides a promising treatment option for patients who do not desire invasive management, but need further trials to fully elucidate its treatment implications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie’s disease: AUA guideline. J Urol. 2015;194:745–53.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol. 2006;175:2115–8 (discussion 2118).

    Article  PubMed  Google Scholar 

  3. Nelson CJ, Mulhall JP. Psychological impact of Peyronie’s disease: a review. J Sex Med. 2013;10:653–60.

    Article  PubMed  Google Scholar 

  4. Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;2011:282503.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ralph D, Gonzalez-Cadavid N, Mirone V, Perovic S, Sohn M, Usta M, et al. The management of Peyronie’s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7:2359–74.

    Article  PubMed  Google Scholar 

  6. Teasley GH. Peyronie’s disease; a new approach. J Urol. 1954;71(5):611–4.

    CAS  PubMed  Google Scholar 

  7. Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol. 2002;168:621–5 (discussion 625–6).

    Article  CAS  PubMed  Google Scholar 

  8. Trost LW, Ates E, Powers M, Sikka S, Hellstrom WJ. Outcomes of intralesional interferon-alpha2B for the treatment of Peyronie disease. J Urol. 2013;190:2194–9.

    Article  CAS  PubMed  Google Scholar 

  9. Glina S, Gelbard MK, Akkus E, Jordan GH, Levine LA. The use of collagenase in the treatment of Peyronie’s disease M.K. Gelbard, A. Lindner, and J.J. Kaufman. J Sex Med. 2007;4:1209–13.

    Article  PubMed  Google Scholar 

  10. Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie’s disease experimental studies. Urol Res. 1982;10:135–40.

    Article  CAS  PubMed  Google Scholar 

  11. Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, et al. Injectable collagenase Clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009;361:968–79.

    Article  CAS  PubMed  Google Scholar 

  12. Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.

    Article  CAS  PubMed  Google Scholar 

  13. Hellstrom WJ, Feldman R, Rosen RC, Smith T, Kaufman G, Tursi J. Bother and distress associated with Peyronie’s disease: validation of the Peyronie’s disease questionnaire. J Urol. 2013;190:627–34.

    Article  PubMed  Google Scholar 

  14. Ziegelmann MJ, Viers BR, McAlvany KL, Bailey GC, Savage JB, Trost LW. Restoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie’s disease. J Urol. 2016;195:1051–6.

    Article  PubMed  Google Scholar 

  15. Poullis C, Shabbir M, Eardley I, Mulhall J, Minhas S. Clostridium histolyticum collagenase: is this revolutionary medical treatment for Peyronie’s disease? BJU Int. 2016;118(2):186–9.

    Article  PubMed  Google Scholar 

  16. Levine LA, Larsen SM. Surgical correction of persistent Peyronie’s disease following collagenase Clostridium histolyticum treatment. J Sex Med. 2015;12:259–64.

    Article  PubMed  Google Scholar 

  17. Yafi FA, Anaissie J, Zurawin J, Sikka SC, Hellstrom WJ. Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase Clostridium histolyticum for Peyronie’s disease. J Sex Med. 2016;13:684–9.

    Article  PubMed  Google Scholar 

  18. Cordon B, Hutchinson R, Hofer M, Broderick G, Lota Y, Morey A (eds). Superior cost effectiveness of penile plication versus intralesional collagenase injection for treatment of Peyronie’s disease deformities. Podium presentation at the American Urological Association (AUA) Annual Conferenc, 6–10 May 2016, San Diego, CA.

  19. Goldstein I, Knoll D, Lipshultz L, Tursi J, Smith T, Kaufman G, et al. Changes in the effects of Peyronie’s disease after treatment with collagenase Clostridium histolyticum according to men with Peyronie’s disease and their female sexual partners. J Urol. 2015;193(4 Suppl. 1):e968–9.

    Article  Google Scholar 

  20. Anaissie J, Yafi F, Traore E, Sikka S, Hellstrom WJG (eds). Survey of patient and partner satisfaction following collagenase Clostridium histolyticum treatment for Peyronie’s disease. Podium presentation at the American Urological Association (AUA) Annual Conference, 6–10 May 2016, San Diego, CA.

  21. Milam D. Positive results with collagenase Clostridium histolyticum treatment in two patients with ventral penile curvature due to Peyronie’s disease. J Sex Med. 2016;13:S55.

    Article  Google Scholar 

  22. Sangkum P, Yafi FA, Kim H, et al. Collagenase Clostridium histolyticum (Xiaflex) for the treatment of urethral stricture disease in a rat model of urethral fibrosis. Urology. 2015;86:647.e1–6.

  23. Anaissie J, Yafi F, DeLay KJ, Traore EJ, Sikka SC, Hellstrom WJG (eds). Impact of number of cycles of collagenase Clostridium histolyticum on outcomes in patients with Peyronie’s disease. Podium presentation at the American Urological Association (AUA) 2016 Annual Meeting, 6–10 May 2016, San Diego, CA.

  24. Anaissie J, Powers MK, Hellstrom WJ, Yafi FA. Collagenase Clostridium histolyticum for the pharmacological management of Peyronie’s disease. Drugs Today (Barc). 2015;51(8):457–68.

    Article  CAS  PubMed  Google Scholar 

  25. Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie’s disease. J Urol. 1985;134(2):280–3.

  26. Gelbard MK, James K, Riach P, et al. Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol. 1993;149(1):56–8.

  27. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie’s disease: a prospective, single-center, non-placebo-controlled study. J Sex Med. 2008;5(1):180–7.

  28. Gelbard M, Lipshultz L, Tursi J, et al. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187(6):2268-74.

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA

    James Anaissie, Wayne J. G. Hellstrom & Faysal A. Yafi

  2. Department of Urology, UC Irvine Medical Center, 333 The City Blvd. W, Suite 2100, Orange, CA, USA

    Faysal A. Yafi

Authors
  1. James Anaissie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wayne J. G. Hellstrom
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Faysal A. Yafi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Faysal A. Yafi.

Ethics declarations

Conflict of interest

James Anaissie and Faysal A. Yafi report no conflicts of interest. Wayne J. G. Hellstrom is a consultant and speaker for Endo Pharmaceuticals.

Funding

James Anaissie, Faysal A. Yafi, and Wayne J. G. Hellstrom report no funding was used for the preparation of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anaissie, J., Hellstrom, W.J.G. & Yafi, F.A. Collagenase Clostridium Histolyticum for the Treatment of Peyronie’s Disease: A ‘Real World’ Clinical Perspective. Drugs 76, 1523–1528 (2016). https://doi.org/10.1007/s40265-016-0649-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-016-0649-1

Keywords

Search

Navigation